NCT02850003已完成1 期
A Phase 1b Open-Label Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel in Subjects With Acne Vulgaris Under Maximal Use Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Evaluators Global Severity Score At Day 15
研究概览
简要总结
Study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.
详细描述
An Open-label study designed to assess the safety and plasma PK of tretinoin and its metabolites from topically applied IDP-120 gel.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 9 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female between the ages of 9 and <17 (16 years 11 months)
- •Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or legal guardian must sign the informed consent.
- •Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment.
- •Subject with facial acne inflammatory lesion count no less than 20 but no more than
- •Subject with facial acne non-inflammatory lesion count no less than 20 but no more than
排除标准
- •Use of an investigational drug or device within 30 days of enrollment, previous participation in a research study with IDP-120 Gel, or participation in a research study concurrent with this study.
- •Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobate, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis.
- •Any underlying disease or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion counts inconclusive.
- •Subjects with a facial beard or mustache that could interfere with the study assessments
- •Subjects with more than 2 facial nodules.
研究组 & 干预措施
IDP-120 Gel
Experimental
Gel
干预措施: IDP-120 Gel (Drug)
结局指标
主要结局
Evaluators Global Severity Score At Day 15
时间窗: 15 Days
Acne severity will be determined by the investigator/evaluator based on the global assessment of the inflammatory and non-inflammatory lesions of facial acne. Evaluations will be graded on a static scale ranging from 0 (clear) to 4 (severe).
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne VulgarisAcneNCT02849860Bausch Health Americas, Inc.20
尚未招募
1 期
Treatment of Topical Ketorolac Gel in Acute Gouty FlareAcute Gouty ArthritisAcute PainGout FlareNCT06273813Novilla Pharmaceuticals30
已完成
1 期
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With AsthmaAsthmaNCT04673630AstraZeneca18
已完成
1 期
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer PatientsCarcinoma, Renal CellNCT00158782GlaxoSmithKline75
暂停
1 期
TRimetazidine for acUte on Chronic Liver Failure STudyAcute-On-Chronic Liver FailureNCT03737448Martin Pharmaceuticals30